Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker

Summary

Bristol Myers is building an AI data center with Nvidia's assistance, positioning itself as the third pharma company to pursue such infrastructure. Novartis's kidney drug is gaining competitive advantage while Samsung Biologics pursues a peptide maker acquisition.